Withdrawal of Neprilysin Inhibition for heart failure in ARNI responders with recovered dilated cardiomyopathy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027682

Enrollment

Unknown

Registered

2019-11-23

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dialated cardiomyopathy

Interventions

continued:Neprilysin Inhibition contineous

ceased:withdrawal Neprilysin Inhibition

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. dilated cardiomyopathy with LVEF 40% or lower, absence of current symptoms of heart failure; 2. aged more than 18 years; 3. administration of sacubitril/valsartan(LCZ696) more than 3 months; 4. all of the patients are informed consent.

Exclusion criteria

Exclusion criteria: 1. pregnancy; 2. estimated glomerular filtration rate less than 30ml/min/1.73m2; 3. severe liver failure; 4. angioedema; 5. moderate or severe valvular heart disease; 6. NT-pro-BNP over the cut-offs for acute heart failure (age 450pg/ml; age between 50-75, NT-pro-BNP > 900pg/ml; age>75, NT-pro-BNP > 1800pg/ml).

Design outcomes

Primary

Measure	Time frame
relapse of dialated cardiomyopathy;	—

Secondary

Measure	Time frame
reconstruction measurements;	—

Countries

China

Contacts

Public ContactYuan Ji

The Affiliated Changzhou Second People's Hospital of Nanjing Medical University

jiyuan1213@aliyun.com+86 13196788055

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026